39 results about "Cytochalasin" patented technology

The invention provides an application of a cytochalasin category compounds in a herbicide and belongs to the technical field of pharmaceutical chemistry. According to the invention, the cytochalasin category compounds includes a compound with any one structure shown in the formula AL-11-18 or a physiologically acceptable salt thereof. The cytochalasin category compounds have phytotoxicity and canbe used as an effective component of a herbicide. Example results show that the cytochalasin category compounds have an inhibition effect on arabidopsis thaliana rooting.

The invention provides a temperature-sensitive vascular thrombosis material capable of performing long-term self-development and a preparation method thereof. The vascular thrombosis material contains gold nano gel and a dispersion medium, wherein the gold nano gel comprises a gold nano particle cytochalasin and a polyacrylamide amide compound temperature-sensitive polymer housing layer coated on the surface of the gold nano particle cytochalasin. The vascular thrombosis material only uses temperature as a phase change regulating and controlling factor, has good biocompatibility, can achieve long-term thrombosis in the blood vessel, has the capability of long-term development, can be used for vascular thrombosis of multiple tumor sites, achieves thrombosis of the aorta and terminal blood vessel, completely blocks blood and cuts off cancer cell blood supply to achieve the tumor suppression purpose.

The invention relates to a preparation method and a purpose of a cytochalasin compound. According to the invention, a novel cytochalasin compound is produced by using Aspergillus flavipes ZHN1-09 in a Guangxi mangrove forest plant Cerbera manghas root mug sample. It is proved by experiments that the compound can be used as cell proliferation inhibitors or antitumor agents.

The invention relates to a cell membrane microvesicle targeting an inflammation region and application of the cell membrane microvesicle, and solves the technical problem that an existing material does not have the characteristic of efficiently targeting the inflammation region. A preparation method of the cell membrane microvesicle comprises the following steps: transfecting an MC-3T3 cell through CXCR4 gene overexpressing lentivirus by utilizing genetic engineering, and proliferating the transfected cell to obtain cells with overpressed membrane receptor CXCR4; culturing the over-expressed CXCR4 MC-3T3 cells, conducting washing, conducting treating with cytochalasin B, and carrying out vortex separation on the cells and cell membrane microvesicles; centrifuging the mixture, separating the cells from the cell membrane microvesicles, collecting supernate, and conducting centrifuging for the second time to obtain the cell membrane microvesicles of the targeted inflammation region. The invention also provides an application of the cell membrane microvesicle of the targeted inflammation region in preparation of a targeted inflammation region material. The method can be used in the field of preparation of drug loading materials.

The invention discloses a reagent kit and method for dissociating an animal embryo. The reagent kit for dissociating an animal embryo disclosed by the invention comprises reagents of which the names are respectively an enzymolysis solution C, an enzymolysis solution D and an enzymolysis solution E, wherein the enzymolysis solution C consists of cytochalasin storing fluid and TrypLE digestive fluid, and the volume ratio of the cytochalasin storing fluid to the TrypLE digestive fluid is (3 to 47) to (3 to:97); the enzymolysis solution D is fluid consisting of fetal calf serums, a pronase solution and a TCM-HEPES buffer solution, and the volume ratio of the fetal calf serums to the pronase solution to the TCM-HEPES buffer solution is (1 to 1 to 1) to (1 to 2 to 1); and the enzymolysis solution E consists of cytochalasin storing fluid and Accutase cell separation fluid, and the volume ratio of the cytochalasin storing fluid to the Accutase cell separation fluid is (3 to 47) to (3 to 97). Experiment proves that when the reagent kit and method disclosed by the invention are used for dissociating the animal embryo, the dissociating efficiency is high, the embryo of an animal of species, which cannot be dissociated by an existing method, can be dissociated, the reagent kit and the method are suitable for the embryos at different developmental stages, and hurt to cells in the dissociating process can also be reduced.

The invention relates to a microbial metabolite and an application technology thereof in the field of drug research, and concretely relates to a preparation method and application of a cytochalasin compound produced by microbial metabolism. The chemical structure of the cytochalasin compound is shown as a formula I, and the cytochalasin compound is prepared by carrying out fermentation culture on Curvularia verruculosa. Experiments show that the compound has anti-tumor activity and can be used as a cell proliferation inhibitor or an anti-tumor preparation. The prepared cytochalasin compound is produced by fermentation culture of microorganisms, and has the characteristics of simplicity in operation, short production period, low cost and the like.

The invention provides a temperature-sensitive vascular thrombosis material capable of performing long-term self-development and a preparation method thereof. The vascular thrombosis material contains gold nano gel and a dispersion medium, wherein the gold nano gel comprises a gold nano particle cytochalasin and a polyacrylamide amide compound temperature-sensitive polymer housing layer coated on the surface of the gold nano particle cytochalasin. The vascular thrombosis material only uses temperature as a phase change regulating and controlling factor, has good biocompatibility, can achieve long-term thrombosis in the blood vessel, has the capability of long-term development, can be used for vascular thrombosis of multiple tumor sites, achieves thrombosis of the aorta and terminal blood vessel, completely blocks blood and cuts off cancer cell blood supply to achieve the tumor suppression purpose.

The invention relates to an induction method for a 'Haida 2#' new variety tetraploid of crassostrea gigas. The induction method comprises the steps of selecting a 'Haida 2#' new variety of crassostreagigas as parent oysters, carrying out manual maturity-promoting culture until the parent oysters are mature, selecting female and male individuals with good gonad development as parent oysters, dissecting for fetching ova, filtering, putting the ova into filtered seawater for maturation, enabling the maturated ova to be fertilized with sperms in the filtered seawater, processing fertilized ova byvirtue of cytochalasin B so as to inhibit the discharging of first polar bodies, after the processing, collecting the fertilized ova, transferring the fertilized ova into an ethanol solution for soaking, finally transferring the fertilized ova into a culture container, and carrying out incubation and larva culture. According to the induction method, the discharging of the first polar bodies of the fertilized ova of the ''Haida 2#'' new variety of a diploid is inhibited by virtue of the cytochalasin B, and the living 'Haida 2#' new variety tetraploids of crassostrea gigas are directly induced,so that the survival rate is greatly increased, and a seedling culturing foundation is provided for the amplified breeding of the 'Haida 2#' new variety tetraploid of crassostrea gigas.

The invention discloses a low-temperature preservation method of a multifunctional 3D recombined skin model. The invention applies cytochalasin B to the solid preservation of the skin model for the first time, and adopts a three-step method for processing. The treatment method can maintain the model during transportation The cell activity in the skin can reduce the hypoxic damage of the cells, so as to ensure the accuracy of the 3D re-skin group model test and the vitality of the cells, and greatly extend the storage time.

The invention discloses a synthesis method of flavipesine A, a cytochalasin compound. The structural formula of the compound is: the synthesis method comprises: 1) dissolving compound B in tetrahydrofuran, adding a reducing agent at room temperature, and reacting at 40°C to obtain Intermediate C; 2) At room temperature, add the reaction reagent to the THF solution of Intermediate C to obtain Compound A. The reagents used in the synthesis process provided by the present invention can be purchased commercially at low prices, and this reaction strategy is also applicable to the synthesis of other types of cytochalasin-like intermediate product derivatives, so as to study the structure modification and structure-activity relationship of this type of alkaloids , New drug development and mass production lay the foundation.

The invention discloses a preparation and identification method of a human leukemia cell cytoplast. The method comprises the following steps of: treating a purified human leukemia HL-60 cell with a cytochalasin and colchicine, centrifugally denucleating at the temperature of 34 DEG C, collecting a cytoplast component, and purifying with a Percoll density gradient centrifugation method to obtain apurified cytoplast; and identifying the cytoplast with DAPI (4',6-diamidino-2-phenylindole) and CFSE (5,6-carboxyflu-orescein diacetate succinimidyl ester) fluorescent double staining. Due to the adoption of the method, the denucleating rate of a non-adherent human leukemia HL-60 cell can be over 90 percent, the purity of purified cytoplasts is over 95 percent, the quantity of cytoplasts which are more than or equal to 5 mum in diameter is up to 81 percent, and a cytoplast which is chromophilic with a CFSE fluorescent probe can be directly applied to subsequent researches; an HL-60 cell cytoplast obtained with the method can be widely applied to researches of leukemia cell cytoplast components as well as metabolism, functions, cell reconstruction, cell differentiation, apoptosis and the like thereof; and the method is suitable for preparing and identifying all in-vitro non-adherent tumor cell cytoplasts.

The invention provides an improved micromanipulation solution for a mitochondrial replacement technology and a preparation method of the improved micromanipulation solution. The improved micromanipulation liquid for the mitochondrial replacement technology is prepared from cytochalasin B, dimethyl sulfoxide and a vitrolite assisted reproduction IVF-gamete treatment liquid, in the improved micromanipulation solution, the concentration of cytochalasin B is greater than 0 mu g / mL and less than 2.5 mu g / mL. According to the improved micromanipulation liquid for the mitochondrial replacement technology, the purpose of improving the effectiveness and safety of the mitochondrial replacement technology is achieved only by adjusting the concentration of cytochalasin B, operation is easy, and safety guarantee is provided for thoroughly blocking maternal-fetal heredity of mitochondrial diseases.